Translate Bio Inc (TBIO) Receives Average Recommendation of “Strong Buy” from Analysts

Translate Bio Inc (NASDAQ:TBIO) has been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price objective of $22.75 for the company and are expecting that the company will post ($0.44) EPS for the current quarter, according to Zacks. Zacks has also assigned Translate Bio an industry rank of 84 out of 255 based on the ratings given to its competitors.

A number of research analysts have recently commented on the company. HC Wainwright assumed coverage on Translate Bio in a research report on Monday, December 24th. They set a “buy” rating and a $21.00 price target on the stock. ValuEngine downgraded shares of Translate Bio from a “buy” rating to a “hold” rating in a report on Friday, December 21st.

Several institutional investors have recently modified their holdings of TBIO. Wells Fargo & Company MN increased its position in Translate Bio by 148.5% during the third quarter. Wells Fargo & Company MN now owns 273,313 shares of the company’s stock worth $2,733,000 after buying an additional 163,313 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Translate Bio in the third quarter valued at about $139,000. BlackRock Inc. lifted its position in shares of Translate Bio by 184.4% in the third quarter. BlackRock Inc. now owns 426,770 shares of the company’s stock valued at $4,268,000 after acquiring an additional 276,715 shares in the last quarter. FMR LLC boosted its stake in shares of Translate Bio by 0.4% during the 3rd quarter. FMR LLC now owns 6,337,361 shares of the company’s stock worth $60,829,000 after purchasing an additional 23,100 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its position in Translate Bio by 112.8% during the third quarter. Sphera Funds Management LTD. now owns 276,639 shares of the company’s stock worth $2,766,000 after acquiring an additional 146,639 shares during the last quarter. Institutional investors own 59.27% of the company’s stock.

NASDAQ:TBIO traded up $0.17 during trading hours on Monday, hitting $13.12. 191,765 shares of the company were exchanged, compared to its average volume of 194,874. The firm has a market cap of $586.29 million and a P/E ratio of -3.60. Translate Bio has a one year low of $4.81 and a one year high of $16.60. The company has a quick ratio of 10.47, a current ratio of 10.47 and a debt-to-equity ratio of 0.83.

Translate Bio (NASDAQ:TBIO) last issued its earnings results on Thursday, March 21st. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.09. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $0.80 million. As a group, equities research analysts expect that Translate Bio will post -1.52 EPS for the current year.

Translate Bio Company Profile

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Read More: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with's FREE daily email newsletter.